Development and Validation of a High Performance Liquid Chromatographic Method for Simultaneous Determination of Ten Process-related Impurities of Clevidipine Butyrate

被引:0
|
作者
Liu Yan-Hua [1 ]
Lu Di-Ya [2 ]
Song Zhi-Yong [3 ]
Zheng Bin-Xing [1 ,2 ]
Zhang Qian-Qian [1 ,2 ]
Lu Feng [2 ]
Xu Ji-Yang [1 ]
机构
[1] China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing 210009, Peoples R China
[2] Second Mil Med Univ, Sch Pharm, Shanghai 200082, Peoples R China
[3] Taiyuan Univ Technol, Inst Coal Chem Engn, Taiyuan 030024, Peoples R China
关键词
Clevidipin Butyrate; High performance liquid chromatography; Quality control; DIHYDROPYRIDINE; HYPERTENSION;
D O I
暂无
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A reversed phase high performance liquid chromatographic (RP-HPLC) method coupled with DAD was developed for the simultaneous determination of ten process. related impurities (PRI) of Clevidipin Butyrate (CLE). The chromatographic separation was carried out on a Waters symmetry C-18 column (250 mm x 4.6 mm, 5 mu m) and all components were monitored at 220 nm. The mobile phase consisted of 0.05 mol/L sodium dihydrogen phosphate with pH 2.5 adjusted by phosphoric acid (MPA) and a mixed solution of acetonitrile and methanol (3.2, V/V). Flow rate was kept at 1.5 mL/min, the injection volume was 20 mu L for all injections, and the column temperature maintained at 35 degrees C. The method was further validated with respect to selectivity, linearity, limit of detection (LOD), limit of quantitation (LOQ), precision and accuracy. A good linearity was obtained in the measured concentration ranges for CLE and ten impurities (r >= 0.9970), and the detection limits were 0.90, 0.24, 0.23, 0.15, 0.18, 0.18, 0.27, 0.82, 0.45, 0.89 and 0.45 mg/L for CLE and ten impurities respectively.
引用
收藏
页码:257 / 263
页数:7
相关论文
共 9 条
  • [1] Aronson S, 2009, ANESTH ANALG, P34
  • [2] Awad AS, 2010, VASC HEALTH RISK MAN, V6, P457
  • [3] In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man
    Ericsson, H
    Tholander, B
    Regårdh, CG
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 8 (01) : 29 - 37
  • [4] Determination of an ultrashort-acting antihypertensive dihydropyridine, clevidipine, in blood using capillary gas chromatography mass spectrometry and of the primary metabolite using liquid chromatography and fluorescence detection
    Fakt, C
    Stenhoff, H
    [J]. JOURNAL OF CHROMATOGRAPHY B, 1999, 723 (1-2): : 211 - 219
  • [5] [李灵 Li Ling], 2010, [中国新药杂志, Chinese Journal New Drugs], V19, P1003
  • [6] Michael S L, 2012, J CARDIOTHOR VASC AN, V26, P526
  • [7] Clevidipine: A new intravenous option for the management of acute hypertension
    Ndefo, Uche Anadu
    Erowele, Goldina Ikezuagu
    Ebiasah, Ruth
    Green, Wendy
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (05) : 351 - 360
  • [8] Clevidipine, an Intravenous Dihydropyridine Calcium Channel Blocker, Is Safe and Effective for the Treatment of Patients With Acute Severe Hypertension
    Pollack, Charles V.
    Varon, Joseph
    Garrison, Norman A.
    Ebrahimi, Ramin
    Dunbar, Lala
    Peacock, W. Frank
    [J]. ANNALS OF EMERGENCY MEDICINE, 2009, 53 (03) : 329 - 338
  • [9] [袁慧雅 Yuan Huiya], 2014, [沈阳药科大学学报, Journal of Shenyang Pharmaceutical University], V31, P369